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ObjectiveaaTo investigate the effects of memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, on cognitive impairments 
in patients with chronic schizophrenia.
MethodsaaA 12-week, placebo-controlled trial was conducted to determine the effectiveness of memantine as an adjunctive treatment 
with conventional antipsychotic medications in 26 patients with chronic schizophrenia. The subjects were evaluated with the Korean 
version of the Mini-Mental State Examination (K-MMSE), the Positive and Negative Syndrome Scale (PANSS), the Hamilton Rating 
Scale for Depression (HAM-D), and a standard neuropsychological screening test.
ResultsaaMemantine treatment was not associated with significantly improved cognitive test scores compared with the placebo control 
treatment. An improvement in the scores on the PANSS negative subscale was noted with memantine, but it was not significant.
ConclusionaaAdjunctive memantine treatment did not improve cognitive functioning or affect psychopathology in patients with 
chronic schizophrenia in the present study. Memantine, however, was tolerated well and did not exacerbate positive symptoms in pa-
tients with chronic schizophrenia.  Psychiatry Investig 2012;9:166-173
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INTRODUCTION
Cognitive impairment represents a core feature of schizo-
phrenia in the majority of patients with the disorder.
1,2 Cogni-
tive deficits appear during the initial episode of the illness
3 
and may appear even in those who are not taking antipsy-
chotic medications,
4,5 suggesting that these deficits do not re-
flect the deteriorative effects of treatment. Cognitive impair-
ment is associated with poor functional outcome and long-
term prognosis.
6 Because cognitive impairment is among the 
strongest predictors of functional outcome in patients with 
schizophrenia,
6,7 the improvement of cognitive functioning 
has been identified as an important goal of treatment.
8,9
Despite the known beneficial effects of conventional anti-
psychotics on positive symptoms, some studies have shown 
that these drugs might have negative effects on cognitive fun-
ctioning,
10,11 although other, more systematic analyses have 
suggested that such drugs provide a modest benefit.
12 Howev-
er, evidence also exists that atypical antipsychotic drugs might 
benefit cognitive functioning. Atypical antipsychotic drugs 
have been associated with greater improvement in cognitive 
functioning than conventional antipsychotic medications,
13-15 
although these benefits were relatively slight and have not been 
consistently shown. Thus, although atypical antipsychotic 
drugs may offer some benefits to cognitive functioning in 
schizophrenia,
17 significant deficits still persist in this domain 
and alternative therapies for enhancing cognitive functioning 
are required.
http://dx.doi.org/10.4306/pi.2012.9.2.166
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Several novel strategies to treat cognitive impairment in 
schizophrenia have been explored. Extensive psychopharma-
cological research has focused on dopamine receptors in the 
prefrontal cortex, nicotinic and muscarinic acetylcholine re-
ceptors, the glutamatergic excitatory synapse, various sero-
tonin receptors, and the γ-aminobutyric acid (GABA) sys-
tem.
18 Previously, Lee and colleagues
19 conducted a placebo-
controlled trial of galantamine, a combined acetylcholine-
sterase inhibitor and allosteric potentiator of the nicotinic 
receptor, to examine the effects of the drug on the cognitive 
functioning of individuals with chronic schizophrenia. This 
trial showed no significant effects on cognitive functioning.
Glutamate is the primary excitatory neurotransmitter for 
approximately 60% of neurons
20 and also plays a principal 
role in modulating long-term potentiation. Moreover, gluta-
mate is considered to be a key cellular mechanism in learning 
and memory.
21 Glutamate dysregulation may be involved in 
the neuropathology of schizophrenia,
22 as evidenced by stud-
ies using N-methyl-D-aspartate (NMDA) receptor antago-
nists, phencyclidine (PCP) and ketamine. PCP and ketamine 
produce the wide range of schizophrenic symptoms, includ-
ing psychotic symptoms, negative symptoms, and cognitive 
impairment.
23,24 NMDA hypofunctioning results in decreased 
stimulation of central GABAergic neurons.
25 This ultimately 
may lead to the excessive release of glutamate into the synapse 
and consequently causes significant neuronal cell death.
26 
Thus, NMDA-mediated neuronal cell death is believed to play 
a role in the pathology of schizophrenia. Therefore, drugs that 
block excessive NMDA receptor-induced glutamate activity 
may attenuate this excitotoxic process.
27
Memantine is currently approved for the treatment of mod-
erate to severe Alzheimer’s disease. It is a moderate affinity, 
noncompetitive, voltage-dependent NMDA receptor antago-
nist with rapid kinetics.
26 These pharmacological features 
might allow memantine to modulate the pathological NMDA 
receptor activity thought to occur in Alzheimer’s disease, 
while permitting normal physiological activation of the re-
ceptor required for learning and memory.
29,30 Memantine is 
clinically well tolerated and lacks the psychotomimetic effects 
seen with other NMDA receptor antagonists such as ketamine 
and PCP.
28,31 Because memantine treatment successfully slows 
neurodegeneration in dementia,
32 it may also have a positive 
impact on the symptoms of schizophrenia.
33 Krivoy and col-
leagues
34 reported that menantine, in combination with con-
ventional antipsychotic treatment, improved the negative sym-
ptoms of schizophrenia. Moreover, de Luceana and colleague
35 
reported that memantine in combination with clozapine ther-
apy was associated with improvement in negative and positive 
symptoms. Lieberman and colleagues,
36 however, reported 
that memantine was not efficacious as an adjunctive therapy.
In this randomized, double blind, placebo-controlled study, 
the potential effects of adjunctive memantine treatment on 
cognitive functioning in chronic schizophrenia was investi-
gated. In addition, patient psychopathology was evaluated, 
and the adverse effects of memantine were assessed. 
METHODS
Subjects 
Subjects aged between 18 and 50 years were recruited from 
seven in-patient units in hospitals located in Busan and Ma-
san, South Korea. The hospitals included Jamyung, Semy-
oung, Dongnae, Daenam, Busan Municipal, Hyungju, and 
Dongsuh. Informed consent was obtained from each patient, 
and the Institutional Review Board at Busan Paik Hospital 
approved the protocol for the present study (Trial Number: 
07-27). All patients were diagnosed with schizophrenia ac-
cording to the standard structured clinical interview for 
DSM-IV Axis I disorders (SCID-I)
37 and had been stabilized 
using conventional antipsychotic medications for a minimum 
of three months prior to this study. The level of cognitive im-
pairment required for participation was defined as a total per-
formance score between 18 and 24 on the Korean version of 
the Mini-Mental Status Examination.
38,39 Subjects with a his-
tory of substance abuse or dependence, head trauma, severe 
neurological disorders, depression, or other medical problems 
were excluded. Although patients who were undergoing treat-
ment with medications that affected cognitive performance 
were also excluded, patients receiving antiparkinsonian anti-
cholinergic or benzodiazepine-based drugs were included if 
the dosing regimen did not change over the 12-week study 
period. Smokers were also included in this study. 
Study design 
Twenty-six subjects were enrolled in the 12-week, double 
blind trial. Simple randomization based on a random-num-
bers table was used to assign subjects to either the placebo or 
the memantine group. Central randomization was also used 
to avoid the center effect. An investigator who was unaware of 
randomization assignments was assigned to each site to guar-
antee the integrity of the double-blind study design. After the 
baseline evaluation, subjects were randomly selected to re-
ceive memantine treatment or a placebo, in addition to a fixed 
daily dose of conventional antipsychotic medication (chlor-
promazine-equivalent dose: 1145 mg/day).
40 Subjects in the 
memantine group received an initial dose of five mg/day, 
which was increased weekly in five mg increments until 
reaching a maximum dose of 20 mg/day. This maximum dose 
was chosen according to the effective dose established for pa-
tients with dementia.
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and secondary outcome (psychiatric symptoms) variables 
were assessed at baseline, week 6, and week 12. The checklist 
for adverse events was completed at weeks 6 and 12. 
Assessment 
The Positive and Negative Symptom Scale
42 and the 17-
item Hamilton Rating Scale for Depression
43 were used to as-
sess the severity of psychiatric symptoms and depressed 
mood. The Clinical Global Impression Severity and Improve-
ment scales (CGI-S and CGI-I) were also administered to all 
subjects. Adverse events in response to memantine treatment 
were assessed using an adverse events checklist, which in-
cluded the adverse events mostly commonly observed in pa-
tients with dementia.
44 A battery of neuropsychological tests 
was administered to evaluate changes in several domains of 
cognitive functioning. The K-MMSE, the Hopkins Verbal 
Learning Test (HVLT), the Rey Complex Figure Test (RCFT), 
the Digit Span Forward and Backward Test, the Digit Symbol 
Substitution Test (DSST), the Stroop test, the Trail Making 
Test (Part A), the Verbal Fluency Test (VFT), and the Boston 
Naming Test were used to assess attention, auditory and visu-
al memory, and executive functioning. The HVLT was also 
used to examine immediate memory span, new learning, sus-
ceptibility to interference, and delayed recall. The VFT was 
used to examine verbal productivity and intactness of the lex-
ical system. 
Analyses 
Baseline comparisons between the two groups were per-
formed using the Mann-Whitney U test for continuous vari-
ables and Fisher’s exact test for categorical variables. The effi-
cacy of memantine and placebo were analyzed with repeated 
measures analysis of variance (ANOVA) using group (me-
mantine versus placebo) as the between-subjects factor and 
time (baseline, week 6, and week 12) as the within-subjects 




Twenty-nine subjects met the eligibility criteria at baseline. 
However, three subjects withdrew their consent after random 
assignment. The remaining 26 subjects were randomly as-
signed to memantine (n=15) or placebo (n=11) treatment 
groups and completed the 12-week trial.
Table 1 presents demographic and baseline data for the 
study population. No significant differences in demographic 
or clinical variables were observed between the treatment 
groups at baseline. The following mean scores±standard de-
viation (SD) were recorded for the memantine versus placebo 
groups, respectively: PANSS: 74.5±14.9, 74.7±14.2; HAM-D: 
1.4±2.0, 2.2±1.8; and K-MMSE: 22.0±1.6, 21.6±1.6. All sub-
jects also received conventional antipsychotic drugs, and the 
mean chlorpromazine-equivalent dose did not differ between 
treatment groups. Fourteen patients (53.8%) received a com-
bination of two antipsychotic drugs. 
Table 1. Demographic and baseline clinical data
  Memantine (N=15) Placebo (N=11)
p-value
Mean±SD Mean±SD
Age (years) 44.3±4.3 43.4±3.9 0.55
Education (years)   9.9±4.1 10.4±3.6 0.90
Duration of illness (months)   171.3±102.6   135.2±135.0 0.13
Daily chlorpromazine equivalent dose (mg)   1261.7±1078.6   986.4±831.6 0.57
Duration of medication (months)   21.6±19.1 16.1±9.3 0.68
Clinical rating scale scores   
PANSS    74.5±14.9   74.7±14.2 0.90
HAM-D    1.4±2.0   2.2±1.8 0.21
K-MMSE  22.0±1.6 21.6±1.6 0.40
CGI-S    4.3±1.0   3.9±1.0 0.33
% %
Gender (% male) 73.3 45.5 0.23
Use of anticholinergic drugs (% subjects)   93.3 90.9 1.00
Smokers (% subjects) 46.7 45.5 1.00
Data were analyzed using the Mann–Whitney U-test for continuous variables and Fisher’s exact test for categorical variables. SD: standard 
deviation, PANSS: Positive and Negative Syndrome Scale, HAM-D: Hamilton Rating Scale for Depression, K-MMSE: Korean version of the 
Mini-Mental State Examination, CGI-S: Clinical Global Impression Ratings-SeverityJG Lee et al. 
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Effect of adjunctive memantine therapy  
on psychiatric symptoms
Psychiatric symptoms at baseline and week 12 did not 
change in response to memantine treatment. Mean PANSS 
scores did not differ between the memantine and placebo 
groups (Table 2). None of the subjects displayed a favorable 
response to memantine treatment in terms of their CGI-S or 
CGI-I scores (i.e., an improvement of ≥2 points). 
Effect of adjunctive memantine therapy  
on K-MMSE scores
The mean K-MMSE score increased from 22.0±1.6 at base-
Table 2. Effects of memantine compared with placebo on psychiatric assessment scores over the 12-week study period
 
Memantine (N=15) Placebo (N=11)
p-value Mean±SD Mean±SD
Baseline Week 12  Baseline Week 12
PANSS
Total   74.5±14.9   73.6±17.5   74.7±14.2   74.3±14.6 0.93
Positive subscale 17.3±6.9 17.9±7.2 18.7±4.9 17.4±4.8 0.33
Negative subscale 21.3±5.0 20.5±5.1 19.8±6.5 20.7±6.5 0.12
General psychopathology subscale 35.1±8.4 35.3±9.1 36.2±7.2 36.2±7.7 0.89
HAM-D   1.4±2.0   0.9±1.3   2.2±1.8   1.6±1.7 0.99
CGI-S   4.3±1.0   4.3±1.0   3.9±1.0   3.7±1.3 0.82
Data were analyzed using repeated measures analysis of variance (ANOVA). p-value was calculated from time by group interaction. SD: stan-
dard deviation, PANSS: Positive and Negative Syndrome Scale, HAM-D: Hamilton Rating Scale for Depression, CGI-S: Clinical Global Im-
pression Ratings-Severity
Table 3. Effects of memantine compared with placebo on measures of cognitive functioning over the 12-week study period
 
Memantine (N=15) Placebo (N=11)
p-value Mean±SD Mean±SD
Baseline Week 12  Baseline Week 12
K-MMSE*    22.0±1.6 24.3±2.8   21.6±1.6   22.7±3.2 0.41
HVLT†
Immediate recall    13.0±5.5 17.5±8.0   12.6±5.2   17.0±5.8 0.24
Delayed recall      4.1±2.7   5.4±4.0     3.8±2.8     5.0±2.9 0.89
Recognition      7.3±3.2   7.5±3.7     5.9±3.0     7.0±2.6 0.70
RCFT*
Immediate recall    17.4±4.5 18.1±5.5   16.4±8.7   17.4±6.9 0.55
Delayed recall      2.5±2.0   4.1±4.0     1.2±1.0     2.9±2.8 0.28
Recognition      5.7±1.9   5.7±2.2     5.2±2.6     5.5±1.8 0.88
Digit Span†
Forward      4.7±1.1   4.7±1.1     5.1±0.9     5.6±1.2 0.45
Backward      2.9±1.0   2.9±1.0     3.0±1.0     3.2±0.8 0.20
DSST†    23.5±9.6   29.5±10.2   19.8±9.0    23.4±7.8 0.06
Stroop test†
Letter  111.8±0.6 106.5±13.2 110.0±3.9 110.0±6.0 0.26
Color      48.2±20.6   66.5±48.5     47.7±22.6      52.9±25.3 0.59
Trail making part A‡      99.6±79.0   78.0±43.2     130.3±105.5   118.1±92.7 0.65
Verbal fluency†    11.8±3.8 13.5±3.4   10.6±3.5   12.2±4.8 0.49
Boston Naming Test†      37.3±11.1   41.0±11.8   40.0±8.6   43.5±9.4 0.71
Data were analyzed using repeated-measures analysis of variance (ANOVA). p-value was calculated from time by group interaction. *Scores, 
†Numbsers, ‡Seconds. K-MMSE: Korean Mini Mental State Examination, SD: standard deviation, HVLT: Hopkin’s Verbal Learning Test, 
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line to 24.3±2.8 at week 12 in the memantine group and from 
21.6±1.6 at baseline to 22.7±3.2 at week 12 in the placebo 
group. However, these increases were not significantly differ-
ent at the end of study period (p=0.41).
Effects of adjunctive memantine therapy  
on impaired cognitive functioning 
Table 3 summarizes the results of the tests of cognitive 
functioning for both groups. No statistically significant differ-
ence was observed between groups in regard to any cognitive 
measure, although several tests indicated slight improvements 
after memantine treatment. In addition, the mean scores for 
immediate and delayed recall on the HVLT increased in the 
memantine group compared to the placebo group, but overall 
scores did not differ between groups at the end of the study 
period. The mean value obtained on the Stroop test was larger 
in the memantine group, but differences between groups did 
not reach statistical significance. The mean score on the Trail 
Making Test decreased in the memantine group compared to 
the placebo group, but the overall scores of the groups did not 
differ at the end of the study period. Improved scores on the 
Boston Naming Test were observed in the memantine group, 
but the between-group difference was not significant. The 
treatment groups did not differ in regard to any other out-
come measures, including the RCFT, the Digit Span Forward 
and Backward Test, and the VFT. 
Adverse events as a result of adjunctive  
memantine therapy
Memantine was well tolerated and the incidence of adverse 
events was similar between groups. In total, 47% of the me-
mantine group and 55% of the placebo group experienced 
adverse events. The most common adverse events were dizzi-
ness, diarrhea, and constipation, but these symptoms were 
transient and mild to moderate in intensity. No subject dem-
onstrated serious adverse effects during the study (Table 4). 
DISCUSSION
The present study investigated the effects of adjunctive me-
mantine therapy in combination with conventional antipsy-
chotic medication in patients with chronic schizophrenia. The 
cognitive functioning profiles of subjects in the present study 
were very similar to the profiles of subjects with dementia re-
ported in previous studies.
45,46 No statistically significant dif-
ferences were observed in the memantine group compared 
with the placebo group. Therefore, these results do not sup-
port the hypothesis that adjunctive memantine therapy im-
proves cognitive functioning. Similarly, adjunctive meman-
tine therapy was not associated with improvements in the 
psychopathology of schizophrenia. Krivoy and colleagues
34 
reported that memantine did not improve cognitive function-
ing during a 6-week open-label study. Lieberman and col-
leagues also reported that memantine adjunctive therapy 
failed to affect cognitive symptoms.
36 In this 8-week random-
ized, placebo-controlled study, memantine was used in com-
bination with antipsychotic medication. Memantine did not 
have an effect on the Brief Assessment of Cognition in Sc-
hizophrenia (BACS) or the PANSS negative score. However, 
de Luceana and colleagues
35 reported significantly increased 
MMSE scores after 12 weeks of adjunctive memantine treat-
ment in combination with clozapine therapy. Krivoy and col-
leagues
34 reported a 21% decrease in the PANSS negative sub-
scale scores. Significant improvement on the negative sub-
scales of the Brief Psychiatry Rating Scale (BPRS) was reported 
by de Luceana and colleagues.
35 Silver and colleagues
47 
showed that amantadine, an antiviral agent with indirect do-
paminergic agonist and NMDA antagonist action, was asso-
ciated with improved visuomotor coordination compared to 
a placebo treatment. However, amantadine did not show ben-
eficial effects on cognitive functioning. Gama and colleagues
48 
reported that adjunctive memantine therapy improved scores 
on the Brief Psychiatric Rating Scale (BPRS) among patients 
with schizophrenia. However, the observed decrease in 
PANSS scores was not significantly different between groups 
in the present study, Despite the absence of data regarding the 
effects of memantine on patients with schizophrenia, me-
mantine, unlike other NMDA receptor antagonists, did not 
induce psychosis. These observations indicate that meman-
tine may represent a safer alternative for patients with schizo-
phrenia.
Previous studies have suggested that the glutamatergic sys-
tem is involved in the pathophysiology and treatment of de-
pression.
49 For this reason, patients with depression were ex-
cluded from the present study. During the study period, no 
significant differences related to depression were observed.
Although a recent study reported that memantine adjunc-
tive therapy was associated with adverse treatment effects,
36 
fewer adverse events were reported with memantine therapy 
in patients with chronic schizophrenia in the present study 
compared with patients with Alzheimer’s dementia (AD). 
Reisberg and colleagues
41 reported adverse events in 84% of 
Table 4. Adverse effects of memantine and placebo
Memantine (N=15) Placebo (N=11)
Dizziness 3 (20%) 2 (18%)
Diarrhea 2 (13%) 2 (18%)
Constipation 2 (13%) 1 (9%)
Headache 0 1 (9%)
Total 7 (47%) 6 (55%)JG Lee et al. 
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memantine-treated AD patients and 87% of placebo-group 
patients. Agitation and urinary tract infections were the most 
common adverse events.
Tariot and colleagues
50 reported that 78% of AD patients 
receiving memantine and 72% of those receiving placebo ex-
perienced adverse events. At least 5% of the memantine 
group, double the proportion found in the placebo group, ex-
perienced confusion and headaches. However, in the current 
study, no differences in adverse events were observed between 
the memantine and placebo groups. This discrepancy be-
tween schizophrenia and AD in the occurrence of adverse 
events might derive from differences in the physiological 
characteristics or ages of subjects.
This study has several limitations. First, most subjects were 
undergoing treatment with anticholinergic drugs during the 
study period. A large body of evidence from human and non-
human animal studies has established that the cholinergic 
neurotransmitter system is important for attention, memory, 
and learning.
51,52 Anticholinergic drugs impair cognitive and 
information processing both in normal populations
53 and in 
individuals with schizophrenia.
54 Moreover, several lines of 
evidence indicate that NMDA antagonists interact with cho-
linergic systems,
55-57 although the interaction between cholin-
ergic and glutamatergic systems is complex and poorly un-
derstood. Second, the majority of subjects in this study were 
chronic and institutionalized patients and might have been 
unresponsive to memantine treatment for this reason. More-
over, the relatively high doses of antipsychotic drugs may have 
resulted in memantine insensitivity. Third, subjects in this 
study were allowed to smoke. It is known that cigarette smok-
ing may enhance cognitive functioning in smokers with schi-
zophrenia.
58 Furthermore, the study duration may have been 
insufficient. Although this study cannot exclude the possibili-
ty of a task-learning effect, memantine therapy tended to 
show a stronger positive effect on cognitive functioning as 
time passed. Memantine treatment has been shown to signif-
icantly improve cognitive functioning for up to 28 weeks
41 
among those with Alzheimer’s dementia. Other studies on the 
effects of memantine on cognitive functioning report im-
provement for 24 weeks.
59,60 Therefore, we can hypothesize 
that the 12-week duration of this study might be too short to 
warrant any conclusions. Finally, the small sample size may 
have masked significant effects. Although this study can be 
regarded as pilot study for a large-scale trial, the implications 
of the results might be restricted, and further study with a 
larger sample is needed.
Cognitive impairment represents a cardinal feature of schi-
zophrenia and a strong predictor of poor vocational and so-
cial outcomes. The level of cognitive impairment is a better 
predictor of functional outcome than is the severity of posi-
tive or negative symptoms. Therefore, an urgent need exists to 
develop therapies that target cognitive deficits. Our findings 
indicate that adjunctive memantine therapy does not have 
beneficial effects on cognitive functioning or psychopatholo-
gy among patients with schizophrenia. However, future stud-
ies that address the limitations described above are required 
to examine more deeply the effects of memantine on cogni-
tive impairment in schizophrenia.
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